← BackUTAH MEDICAL PRODUCTS INC · Surgical & Medical Instruments & ApparatusUTMD
Low riskNext report: Around Jan 28, 2027 (est.)
The short versionA high-quality, profitable business with shrinking sales. Institutions are adding.
Going well
- Profitable every year for 10 years
- Brings in more cash than it spends
- Buying back shares: share count down 11% in 3 years
Watch out for
- Sales down 14% in the latest quarter vs a year ago
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 2.3% to their holdings in the quarter ending June 2026 (55 bought, 44 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$73.46-1.0% that day
- Company value
- $234M
- Share price times all shares
- Price vs profit (P/E)
- 22.4x
- You pay about $22 for each $1 of yearly profit
- Price vs sales
- 6.5x
- Company value is 6.5 times a year of sales
- Cash vs value
- 37%
- A big cushion: cash is a large part of what the company is worth
From UTMD's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$8.5M-14% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $36.1M, down 7.0% from the 12 months before. Over 5 years, sales shrank about 1.8% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.9.5%
- PassDebt under half of equityNot relying on borrowed money.0.00x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.29.3%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$14.3M
- PassShare count not growingNot diluting owners. Falling means buybacks.-11.1% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.57.1%
- Revenue
- $38.5M
- -5.8% vs prior year
- 5-year growth
- -1.8%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 37.62x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Sep 30, 2026Reported Oct 22During market3:10 pm ET - Revenue
- $8.6M
- -12.1% YoY
- Op. margin
- 32.4%
- +5.8 pts
- Gross margin
- 56.1%
- -1.0 pts
From the press release, checked against last year's SEC filing. Cash flow and share count update with the 10-Q.
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
54/ 100
- This week
- 1
- Normal week
- 0.8
- vs normal
- 1.2x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+2.3%Institutions added 2.3% to their holdings. 55 bought, 44 sold. 2 quarters of net buying in a row.
Shares held by institutions2.3M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-4.3%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.0x · $195K debtShares outstandingLatest reported
3MNext reportAround Jan 28, 2027 (est.)Estimated from the same quarter last year
- Results filedOct 22
- Results filedJul 23
- Results filedApr 23
- Results filedJan 29
- Results filedOct 23, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.